Abivax eyes $49M IPO to advance Cuban-made hep B vaccine

 

Abivax, a Paris-based biotech that acquired the rights to three commercial, Cuban-made vaccines in November, is gearing up for a €43.6 million ($49 million) IPO to take its hepatitis B candidate into Phase III. The cash will also go toward an HIV drug...

 

 

 

Press contacts

Caroline Carmagnol 

abivax@alizerp.com

+ 33 6 64 18 99 59 or
+ 33 1 44 54 36 65

 Standard: +33 1 53 83 08 41

More articles in French

Click here